We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-9.61%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.31B
AUM Growth
-$535M
Cap. Flow
-$185M
Cap. Flow %
-8.02%
Top 10 Hldgs %
64.82%
Holding
66
New
3
Increased
1
Reduced
14
Closed
7

Top Buys

Rank Stock Value
1
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$34.4M
2
VALN
Valneva
VALN
+$11M
3
ELEV
Elevation Oncology
ELEV
+$6.14M
4
MRUS
Merus
MRUS
+$5.9M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$61.1M
2
AMRS
Amyris Inc.
AMRS
+$22.7M
3
AKRO
Akero Therapeutics
AKRO
+$19.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$18.4M
5
EPIX
ESSA Pharma
EPIX
+$15M

Sector Composition

Rank Sector Weight
1 Healthcare 84.84%
2 Materials 8.25%
3 Financials 6.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORTX
51
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.82M 0.25%
132,574
– –
IMVT icon
52
Immunovant
IMVT
$7.91B
$5.63M 0.24%
532,847
– –
SNDX icon
53
Syndax Pharmaceuticals
SNDX
$1.7B
$5.49M 0.24%
320,000
– –
TXG icon
54
10x Genomics
TXG
$5.97B
$2.9M 0.13%
14,798
– –
CALT
55
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$1.83M 0.08%
62,306
-248,724
-80% -$7.12M
ZGNX
56
DELISTED
Zogenix, Inc.
ZGNX
$1.81M 0.08%
105,000
– –
DTIL icon
57
Precision BioSciences
DTIL
$182M
$1.76M 0.08%
4,675
– –
TCDA
58
DELISTED
Tricida, Inc. Common Stock
TCDA
$755K 0.03%
174,763
– –
MTCR
59
DELISTED
Metacrine, Inc. Common Stock
MTCR
$556K 0.02%
146,426
– –
AKRO
60
DELISTED
Akero Therapeutics
AKRO
– –
-673,280
Closed -$19.5M
ATRC icon
61
AtriCure
ATRC
$1.97B
– –
-64,573
Closed -$4.23M
CGEM icon
62
Cullinan Oncology
CGEM
$999M
– –
-250,000
Closed -$10.4M
IGMS
63
DELISTED
IGM Biosciences
IGMS
– –
-20,000
Closed -$1.53M
KALA icon
64
KALA BIO
KALA
$14.6M
– –
-315
Closed -$5.3M
YARW
65
Yarrow Bioscience, Inc. Common Stock
YARW
$22.4M
– –
-261
Closed -$1.61M
CNST
66
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-140,298
Closed -$3.28M
1 2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Vivo Capital held 66 positions worth $2.31B, down 19% from $2.85B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Vivo Capital withdrew a net $185M in Q2 2021, closing 7 positions and reducing 14 holdings. Its most notable exit was Akero Therapeutics, an estimated $19.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier, followed by Materials and Financials.

Against the trend, Vivo Capital opened a new position in Impel Pharmaceuticals Inc. Common Stock worth $25.5M.

  • Vivo Capital's largest Q2 2021 buy was Impel Pharmaceuticals Inc. Common Stock: 2,884,789 shares worth $25.5M.
  • Vivo Capital added most to Merus in Q2 2021, an estimated $5.9M increase.
  • Vivo Capital's biggest Q2 2021 reduction was Legend Biotech, cutting an estimated $61.1M.
  • Vivo Capital fully exited Akero Therapeutics in Q2 2021, selling an estimated $19.5M.
  • Vivo Capital's ten largest holdings make up 65% of its $2.31B portfolio in Q2 2021.
  • Vivo Capital opened 3 new positions and closed 7 in Q2 2021.
  • Vivo Capital's portfolio value fell 19% quarter-over-quarter to $2.31B.

Based on Vivo Capital's 13F filing for Q2 2021, filed 16 Aug 2021.